Synaps research teams focus on implementing an European multicentre controlled clinical trial to proove the efficacy of photodynamic therapy to treat glioblastoma. Our goal: bring a novel therapy to thousands of patients across the world.
Synaps Network develops a controlled clinical trial, in order to repurpose the 5-Amino-Levulinic Acid (5-ALA) molecule in therapy according to methodological developments achieved in preclinical studies.

This new therapy is developed in accordance to Orphan Medicinal Product regulations in the EU supported by the European Medicine Agency (EMA).
​
  • The primary objective will be to demonstrate in a multicentric, parallel-group, randomized controlled trial (RCT) the efficacy of 5-ALA PDT for the treatment of newly diagnosed GBM
  • The secondary objective is the study of biomarkers of GBM progression and response to PDT treatment.

Major neuro-oncology European teams are to join the consortium to extend the enrollment of patients for the trial and ensure timely completion of the recruitment.
Get involved in our clinical trials

Synaps is looking for partners to set up its first multi-centre clinical trials. Do not hesitate to get in touch with us to involve your institution.
Picture
Copyright CHRU Lille
Picture
Copyright ONCO-THAI

Ongoing clinical trial on PDT supported by Synaps

INDYGO: pilot study to assess feasibility and safety of intraoperative 5-aminolevulinic acid mediated photodynamic (5-ALA PDT) therapy for the treatment of newly diagnosed glioblastoma (GBM)

Other clinical trials involving Synaps partners

RESECT: medico-economic evaluation of surgery guided by fluorescence for the optimization of resection of glioblastomas 
Bevacizumab and Lomustine for Recurrent GBM: the primary objective of this study is to investigate whether the addition of bevacizumab to lomustine improves overall survival (OS) in patients with recurrent glioblastoma compared to treatment with lomustine alone
INTELLANCE 2: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma
CheckMate 498: study of Nivolumab Compared to Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma